1Pories WJ. Diabetes: the evolution of a new paradigm[J].Ann Surg, 2004, 239(1):12-13.
2Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus[J]. Ann Surg, 2003, 238(4):467-484,discussion 84-85.
3Ferchak CV, Meneghini LF. Obesity, bariatric surgery and type 2 diabetes--a systematic review[J]. Diabetes Metab Res Rev,2004,20(6):438-445.
4Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution[J].J Clin Endocrinol Metab,2004,89(6):2608-2615.
5Sugerman HJ, Wolfe LG, Sica DA, et al. Diabetes and hypertension in severe obesity and efects of gastric bypass-induced weight loss[J]. Ann Surg,2003,237(6):751-756.
6Flatt PR. Effective surgical treatment of obesity may be mediated by ablation of the lipogenic gut hormone gastric inhibitory polypeptide (GIP): evidence and clinical opportunity for development of new obesity-diabetes drugs? [J]. Diab Vasc Dis Res, 2007, 4(2): 151-153.
7Rubino F. Is type 2 diabetes an operable intestinal disease? A provocative yet reasonable hypothesis[J].Diabetes Care, 2008, 31(Suppl 2): S290-296.
8Pender C, Goldfine ID, Tanner C J, et al. Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia[J]. Int J Obes Relat Metab Disord,2004, 28(3):363-369.
9Houmard JA, Tanner C J, Yu C, et al. Effect of weight loss on insulin sensitivity and intramuscular long-chain fatty acyl- CoAs in morbidly obese subjects[J]. Diabetes,2002, 51 ( 10):2959-2963.
10Zhou H, Yamada Y, Tsukiyama K, et al. Gastric inhibitory polypeptide modulates adiposity and fat oxidation under diminished insulin action[J]. Biochem Biophys Res Commun, 2005,335(3):937-942.
